Among the emerging immune-relevant biomarkers for anti-PD-1/PD-L1 immunotherapy, the expression of PD-L1 on tumor and immune cells is one of the most plausible biomarkers, since it represents the extent of T cell infiltration in the tumor microenvironment [46–48]. This evidence concerns the gene CD274 and neoplasm.